

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

**SCHEDULE 14A**

(RULE 14a-101)  
INFORMATION REQUIRED IN  
PROXY STATEMENT

**SCHEDULE 14A INFORMATION**

Proxy Statement Pursuant to Section 14(a) of the  
Securities Exchange Act of 1934  
(Amendment No. )

Filed by the Registrant

Filed by a Party other than the Registrant

Check the appropriate box:

- Preliminary Proxy Statement
- Confidential, For Use of the Commission Only (as permitted by Rule 14a-6(e)(2))**
- Definitive Proxy Statement
- Definitive Additional Materials
- Soliciting Material Pursuant to § 240.14a-12

**MANKIND CORPORATION**

(Name of Registrant as Specified in its Charter)

N/A

(Name of Person(s) Filing Proxy Statement, if Other Than the Registrant)

Payment of Filing Fee (Check all boxes that apply):

- No fee required.
  - Fee paid previously with preliminary materials.
  - Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11.
-

**mannkind**

1 CASPER STREET  
DANBURY, CT 06810

V45604-P05211

# Your **Vote** Counts!

**MANNKIND CORPORATION**

2024 Annual Meeting

Vote by May 14, 2024

11:59 PM ET



## You invested in MANNKIND CORPORATION and it's time to vote!

You have the right to vote on proposals being presented at the Annual Meeting. **This is an important notice regarding the availability of proxy material for the stockholder meeting to be held on May 15, 2024.**

### Get informed before you vote

View the Annual Report and Notice and Proxy Statement online OR you can receive a free paper or email copy of the material(s) by requesting prior to May 1, 2024. If you would like to request a copy of the material(s) for this and/or future stockholder meetings, you may (1) visit [www.ProxyVote.com](http://www.ProxyVote.com), (2) call 1-800-579-1639 or (3) send an email to [sendmaterial@proxyvote.com](mailto:sendmaterial@proxyvote.com). If sending an email, please include your control number (indicated below) in the subject line. Unless requested, you will not otherwise receive a paper or email copy.



For complete information and to vote, visit [www.ProxyVote.com](http://www.ProxyVote.com)

Control #

#### Smartphone users

Point your camera here and vote without entering a control number



#### Vote Virtually at the Meeting\*

May 15, 2024  
10:00 AM EDT

Virtually at:  
[www.virtualshareholdermeeting.com/MNKD2024](http://www.virtualshareholdermeeting.com/MNKD2024)

\*Please check the meeting materials for any special requirements for meeting attendance.

## THIS IS NOT A VOTABLE BALLOT

This is an overview of the proposals being presented at the upcoming stockholder meeting. Please follow the instructions on the reverse side to vote these important matters.

Voting Items	Board Recommends										
<p>1. To elect the nine nominees named herein as directors to serve for the ensuing year and until their successors are elected;</p> <p><b>Nominees:</b></p> <table border="0"><tr><td>01) James S. Shannon, M.D., MRCP (UK)</td><td>06) Anthony Hooper</td></tr><tr><td>02) Michael E. Castagna, Pharm.D.</td><td>07) Sabrina Kay, Ed.D.</td></tr><tr><td>03) Ronald J. Consiglio</td><td>08) Kent Kresa</td></tr><tr><td>04) Michael A. Friedman, M.D.</td><td>09) Christine Mundkur</td></tr><tr><td>05) Jennifer Grancio</td><td></td></tr></table>	01) James S. Shannon, M.D., MRCP (UK)	06) Anthony Hooper	02) Michael E. Castagna, Pharm.D.	07) Sabrina Kay, Ed.D.	03) Ronald J. Consiglio	08) Kent Kresa	04) Michael A. Friedman, M.D.	09) Christine Mundkur	05) Jennifer Grancio		<input checked="" type="checkbox"/> For
01) James S. Shannon, M.D., MRCP (UK)	06) Anthony Hooper										
02) Michael E. Castagna, Pharm.D.	07) Sabrina Kay, Ed.D.										
03) Ronald J. Consiglio	08) Kent Kresa										
04) Michael A. Friedman, M.D.	09) Christine Mundkur										
05) Jennifer Grancio											
<p>2. To approve, on an advisory basis, the compensation of the named executive officers of MannKind, as disclosed in MannKind's proxy statement for the Annual Meeting;</p>	<input checked="" type="checkbox"/> For										
<p>3. To ratify the selection by the Audit Committee of the Board of Directors of Deloitte &amp; Touche LLP as the independent registered public accounting firm of MannKind for its fiscal year ending December 31, 2024; and</p>	<input checked="" type="checkbox"/> For										
<p>4. To transact such other business as may properly come before the meeting or any adjournment or postponement thereof.</p>											

Prefer to receive an email instead? While voting on [www.ProxyVote.com](http://www.ProxyVote.com), be sure to click "Delivery Settings".

